In combination with BCLxL/BCL2 inhibitors, splicing modulators can enhance cytotoxicity through broader inhibition of the BCL2 family genes that act cooperatively to promote anti-apoptosis/pro-survival in cancer cells (Aird et al, 2019). The gene discussed is BCL2; the disease is cancer.